NCT01766583View on ClinicalTrials.gov

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2018

Conditions
Relapsed/Refractory B-cell Lymphoma
Interventions
DRUG

CC-292 + lenalidomide

CC-292 + lenalidomide

Trial Locations (6)

13273

Institut Paoli Calmette, Marseille

31059

CHU de Toulouse, Toulouse

44093

CHU de Nantes, Nantes

59037

CHU de Lille, Lille

69495

CHU Lyon Sud, Pierre-Bénite

94010

Hopital henri mondor, Créteil

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

The Lymphoma Academic Research Organisation

OTHER

NCT01766583 - A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma | Biotech Hunter | Biotech Hunter